We are a clinical stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products based on our proprietary Tri-specific Killer Engager (TriKE ), and Tetra-specific Killer Engager (Dual Targeting TriKE) fusion protein immune cell engager technology platforms. Our TriKE and Dual Targeting TriKE platforms generate proprietary therapeutics designed to harness and enhance the cancer killing abilities of a patients own natural killer cells (NK cells)....
Q2 FY2026 — expected 2026-09-23
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-02 | 2025-12-31 | 0001493152-26-008443 | EDGAR | 63K words |
| 2025-02-21 | 2024-12-31 | 0001493152-25-007908 | EDGAR | — |
| 2024-03-26 | 2023-12-31 | 0001493152-24-011332 | EDGAR | — |
| 2023-03-30 | 2022-12-31 | 0001493152-23-009812 | EDGAR | — |
| 2022-03-28 | 2021-12-31 | 0001493152-22-007883 | EDGAR | — |
| 2021-04-16 | 2020-12-31 | 0001654954-21-004295 | EDGAR | — |
| 2020-03-27 | 2019-12-31 | 0001654954-20-003380 | EDGAR | — |
| 2019-03-29 | 2018-12-31 | 0001654954-19-003697 | EDGAR | — |
| 2018-03-01 | 2017-12-31 | 0001654954-18-002054 | EDGAR | — |
| 2017-03-31 | 2016-12-31 | 0001654954-17-002919 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-14 | 2025-09-30 | 0001493152-25-023400 | EDGAR | 26K words |
| 2025-08-14 | 2025-06-30 | 0001493152-25-011971 | EDGAR | — |
| 2025-05-15 | 2025-03-31 | 0001641172-25-010790 | EDGAR | — |
| 2024-11-14 | 2024-09-30 | 0001493152-24-045892 | EDGAR | — |
| 2024-08-14 | 2024-06-30 | 0001493152-24-032143 | EDGAR | — |
| 2024-05-15 | 2024-03-31 | 0001493152-24-019970 | EDGAR | — |
| 2023-11-01 | 2023-09-30 | 0001493152-23-038957 | EDGAR | — |
| 2023-08-07 | 2023-06-30 | 0001493152-23-026973 | EDGAR | — |
| 2023-05-15 | 2023-03-31 | 0001493152-23-017492 | EDGAR | — |
| 2022-10-31 | 2022-09-30 | 0001493152-22-030019 | EDGAR | — |
| 2022-08-15 | 2022-06-30 | 0001493152-22-022629 | EDGAR | — |
| 2022-05-16 | 2022-03-31 | 0001493152-22-013539 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-02 | 0001493152-26-008442 | EDGAR | 3K words |
| 2025-11-26 | 0001493152-25-025162 | EDGAR | — |
| 2025-11-14 | 0001493152-25-022631 | EDGAR | — |
| 2025-09-26 | 0001493152-25-015725 | EDGAR | — |
| 2025-09-23 | 0001493152-25-014684 | EDGAR | — |
| 2025-08-29 | 0001493152-25-012479 | EDGAR | — |
| 2025-07-24 | 0001641172-25-020847 | EDGAR | — |
| 2025-06-11 | 0001641172-25-014700 | EDGAR | — |
| 2025-05-27 | 0001641172-25-012481 | EDGAR | — |
| 2025-05-13 | 0001641172-25-009941 | EDGAR | — |
400 total filings indexed. 368 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0000109657 |
| Ticker | GTBP |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.gtbiopharma.com |
| Listed | 2021-02-11 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report